about
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.Potential targeting of B7-H4 for the treatment of cancer.ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 ComplexAdvanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Joseph R Podojil
@en
Joseph R Podojil
@nl
type
label
Joseph R Podojil
@en
Joseph R Podojil
@nl
prefLabel
Joseph R Podojil
@en
Joseph R Podojil
@nl
P31
P496
0000-0002-5818-8515